JP2007523209A - 骨代謝回転が高い個体において骨粗鬆症を治療または予防する方法 - Google Patents
骨代謝回転が高い個体において骨粗鬆症を治療または予防する方法 Download PDFInfo
- Publication number
- JP2007523209A JP2007523209A JP2007500232A JP2007500232A JP2007523209A JP 2007523209 A JP2007523209 A JP 2007523209A JP 2007500232 A JP2007500232 A JP 2007500232A JP 2007500232 A JP2007500232 A JP 2007500232A JP 2007523209 A JP2007523209 A JP 2007523209A
- Authority
- JP
- Japan
- Prior art keywords
- measured
- bone
- marker
- bone resorption
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 18
- 230000008416 bone turnover Effects 0.000 title claims description 29
- 238000011282 treatment Methods 0.000 claims abstract description 16
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 claims abstract description 15
- 229960003969 ospemifene Drugs 0.000 claims abstract description 12
- 239000002207 metabolite Substances 0.000 claims abstract description 10
- 150000002148 esters Chemical class 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 208000006386 Bone Resorption Diseases 0.000 claims description 37
- 230000024279 bone resorption Effects 0.000 claims description 36
- 239000003550 marker Substances 0.000 claims description 28
- 230000011164 ossification Effects 0.000 claims description 20
- 210000002966 serum Anatomy 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 16
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims description 16
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims description 16
- 210000002700 urine Anatomy 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 7
- 108010022452 Collagen Type I Proteins 0.000 claims description 6
- 102000012422 Collagen Type I Human genes 0.000 claims description 6
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 claims description 6
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims description 6
- 108010050808 Procollagen Proteins 0.000 claims description 4
- 108010048038 N-propeptide type I collagen Proteins 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 abstract description 2
- 206010067994 Mucosal atrophy Diseases 0.000 abstract 1
- 206010040799 Skin atrophy Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 description 46
- 210000002997 osteoclast Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 229940011871 estrogen Drugs 0.000 description 9
- 239000000262 estrogen Substances 0.000 description 9
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 230000001833 anti-estrogenic effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- 206010065687 Bone loss Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001076 estrogenic effect Effects 0.000 description 4
- 229960005026 toremifene Drugs 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 206010027304 Menopausal symptoms Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010067572 Oestrogenic effect Diseases 0.000 description 2
- LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 229950004203 droloxifene Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MCJKBWHDNUSJLW-VHXPQNKSSA-N N,N-Didesmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN)=CC=1)/C1=CC=CC=C1 MCJKBWHDNUSJLW-VHXPQNKSSA-N 0.000 description 1
- NYDCDZSEEAUOHN-IZHYLOQSSA-N N-Desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=CC=C1 NYDCDZSEEAUOHN-IZHYLOQSSA-N 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 1
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- BPHFBQJMFWCHGH-QPLCGJKRSA-N alpha-Hydroxytamoxifen Chemical compound C=1C=CC=CC=1/C(C(O)C)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 BPHFBQJMFWCHGH-QPLCGJKRSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/783,092 US20050187302A1 (en) | 2004-02-23 | 2004-02-23 | Method for treatment or prevention of osteoporosis in individuals with high bone turnover |
| PCT/FI2005/000034 WO2005079776A1 (en) | 2004-02-23 | 2005-01-19 | Method for treatment or prevention of osteoporosis in individuals with high bone turnover |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007523209A true JP2007523209A (ja) | 2007-08-16 |
| JP2007523209A5 JP2007523209A5 (enExample) | 2008-03-06 |
Family
ID=34861145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007500232A Abandoned JP2007523209A (ja) | 2004-02-23 | 2005-01-19 | 骨代謝回転が高い個体において骨粗鬆症を治療または予防する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050187302A1 (enExample) |
| EP (1) | EP1718287A1 (enExample) |
| JP (1) | JP2007523209A (enExample) |
| CN (1) | CN1972680A (enExample) |
| AU (1) | AU2005215173A1 (enExample) |
| BR (1) | BRPI0507912A (enExample) |
| CA (1) | CA2557116A1 (enExample) |
| MX (1) | MXPA06009549A (enExample) |
| NO (1) | NO20064007L (enExample) |
| RU (1) | RU2006133903A (enExample) |
| WO (1) | WO2005079776A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011508228A (ja) * | 2007-12-28 | 2011-03-10 | エフ．ホフマン−ラ ロシュ アーゲー | 生理学的状態の評価 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
| WO2007092433A2 (en) * | 2006-02-06 | 2007-08-16 | Tethys Bioscience, Inc. | Osteoporosis associated markers and methods of use thereof |
| KR101510646B1 (ko) * | 2007-02-14 | 2015-04-10 | 호르모스 메디칼 리미티드 | 치료적으로 유용한 트리페닐부텐 유도체의 제조 방법 |
| US7504530B2 (en) * | 2007-02-14 | 2009-03-17 | Hormos Medical Ltd. | Methods for the preparation of fispemifene from ospemifene |
| CN102690347B (zh) * | 2012-05-18 | 2014-06-25 | 北京北方生物技术研究所 | 分离i型前胶原氨基末端肽的方法 |
| EP2909164A1 (en) | 2012-10-19 | 2015-08-26 | Fermion Oy | A process for the preparation of ospemifene |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
| US6245819B1 (en) * | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
-
2004
- 2004-02-23 US US10/783,092 patent/US20050187302A1/en not_active Abandoned
-
2005
- 2005-01-19 JP JP2007500232A patent/JP2007523209A/ja not_active Abandoned
- 2005-01-19 CA CA002557116A patent/CA2557116A1/en not_active Abandoned
- 2005-01-19 WO PCT/FI2005/000034 patent/WO2005079776A1/en not_active Ceased
- 2005-01-19 BR BRPI0507912-8A patent/BRPI0507912A/pt not_active IP Right Cessation
- 2005-01-19 CN CNA2005800049712A patent/CN1972680A/zh active Pending
- 2005-01-19 AU AU2005215173A patent/AU2005215173A1/en not_active Abandoned
- 2005-01-19 EP EP05708122A patent/EP1718287A1/en not_active Ceased
- 2005-01-19 RU RU2006133903/14A patent/RU2006133903A/ru not_active Application Discontinuation
- 2005-01-19 MX MXPA06009549A patent/MXPA06009549A/es unknown
-
2006
- 2006-09-06 NO NO20064007A patent/NO20064007L/no not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011508228A (ja) * | 2007-12-28 | 2011-03-10 | エフ．ホフマン−ラ ロシュ アーゲー | 生理学的状態の評価 |
| US9395355B2 (en) | 2007-12-28 | 2016-07-19 | Roche Diagnostics Operations, Inc. | Assessment of physiological conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1718287A1 (en) | 2006-11-08 |
| BRPI0507912A (pt) | 2007-07-10 |
| WO2005079776A1 (en) | 2005-09-01 |
| NO20064007L (no) | 2006-09-21 |
| AU2005215173A8 (en) | 2009-09-24 |
| CA2557116A1 (en) | 2005-09-01 |
| AU2005215173A1 (en) | 2005-09-01 |
| US20050187302A1 (en) | 2005-08-25 |
| RU2006133903A (ru) | 2008-03-27 |
| CN1972680A (zh) | 2007-05-30 |
| MXPA06009549A (es) | 2007-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2519642C2 (ru) | Способы лечения и/или подавления прироста массы | |
| EP1390040B1 (en) | Pharmaceutical composition for use in hormone replacement therapy | |
| CA2467222C (en) | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy | |
| CN1239160C (zh) | 共轭雌激素和醋酸甲羟孕酮的组合物及其用途 | |
| Mann et al. | 17α-Estradiol prevents ovariectomy-mediated obesity and bone loss | |
| Robertson | ICI 182,780 (Fulvestrant™)–the first oestrogen receptor down-regulator–current clinical data | |
| EP1322336B1 (en) | Method of increasing testosterone and related steroid concentrations in women | |
| JP6532754B2 (ja) | エストロゲン関連疾患を治療するまたは予防するための方法 | |
| AU2002336245B2 (en) | Hormone replacement therapy | |
| AU2001258449B2 (en) | Method for the treatment of climacteric disorders in women during or after the menopause | |
| KR20190025752A (ko) | 선택적 에스트로겐 수용체 조절자와 복합된 성 스테로이드 전구체에 의한 알츠하이머병, 인지 상실, 기억 상실 및 치매의 치료 | |
| JP2003534375A (ja) | 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法 | |
| López | New approaches to the treatment of osteoporosis | |
| JP2007523209A (ja) | 骨代謝回転が高い個体において骨粗鬆症を治療または予防する方法 | |
| JP3621095B2 (ja) | １７α−ジヒドロエキレニンのコレステロールを低下させるための使用 | |
| KR20030090673A (ko) | 에스트로겐 대체 요법 | |
| JP4362442B2 (ja) | 女性における萎縮の抑制方法または萎縮関連症状の治療または予防方法 | |
| CN1668310A (zh) | 使用结合型雌激素和曲美孕酮的联合给药形式的激素替代疗法 | |
| CN1668309A (zh) | 用于治疗绝经后疾病的曲美孕酮和雌激素 | |
| US20030191103A1 (en) | Hormone replacement therapy | |
| KR20070019700A (ko) | 높은 골 전환을 가진 개인에서 골다공증의 치료 또는예방을 위한 방법 | |
| US20030191097A1 (en) | Hormone replacement therapy | |
| CN1151792C (zh) | 抗雌激素在制备男性节育药物中的应用 | |
| US20030229063A1 (en) | Use of 4-hydroxytestosterone to lower estrogen levels in humans | |
| Nishibe et al. | Comparison of effects of estriol on bone mineral density of vertebrae between elderly and postmenopausal women |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080116 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20100820 |